drugset / Trial / NCT00472641

Geodon in Weight Loss Study for Bipolar Disorders

NCT00472641

Phase 4 Completed 25 enrolled Stanford University Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is designed to determine if replacing your current antipsychotic and/or mood stabilizer with ziprasidone (Geodon) will impact weight. This research is being conducted because Geodon has a documented effect on mood. Additionally, we believe Geodon to be an effective medication for overweight or obese patients with bipolar disorder. There will be approximately 25 patients enrolled in this study.

Timeline

Start
2007-01
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 320 mg

Indications